A new study found that part of the Epstein-Barr virus mimics a protein made in the brain and spinal cord, leading the immune ...
Merck & Co has entered into a worldwide licensing deal with Opko Health’s ModeX Therapeutics unit for a vaccine candidate against Epstein-Barr virus (EBV) that could be worth up to $922.5 ...